Patents Examined by Shelly J. Guest
-
Patent number: 5260434Abstract: An IgE-binding protein, .epsilon.BP, which contains two domains: the amino-terminal domain (140 amino acids) consists of a highly conserved repetitive amino acid sequence, Tyr-Pro-Gly-Pro/Gln-Ala/Thr-Pro-Ala-Pro-Gly-Ala, whereas the carboxyl-terminal domain (122 amino acids) shares significant sequence homology with a domain of lymphocyte/macrophage receptor for the Fc portion of IgG is disclosed.Type: GrantFiled: July 10, 1991Date of Patent: November 9, 1993Assignee: The Scripps Research InstituteInventor: Fu-Tong Liu
-
Patent number: 5239060Abstract: The invention relates to a muscular dystrophy (MD) probe comprising a substantially purified single-stranded nucleic acid sequence capable of hybridizing to a region of DNA on a human X chromosome between the deletion break point at Xp21.3 and the translocation break point at X;11. The invention also relates to a 14 kb cDNA corresponding to the complete MD gene and probes produced therefrom useful in genetic methods of diagnosis of MD. Furthermore, the invention relates to the polypeptide, dystrophin, which corresponds to the MD gene product, and antibodies thereto that are useful in a variety of methods for immunodiagnosis of MD.Type: GrantFiled: December 22, 1987Date of Patent: August 24, 1993Assignee: The Children's Medical Center CorporationInventors: Louis M. Kunkel, Anthony Monaco, Eric P. Hoffman, Michel Koenig
-
Patent number: 5231166Abstract: Endothelin-2 and a big type of endothelin-2 proteins are described. The proteins contain the amino acid sequence: Cys Ser Cys Ser Ser Trp Leu Asp Lys Glu Cys Val Tyr Phe Cys His Leu Asp Ile Ile Trp.Type: GrantFiled: October 16, 1989Date of Patent: July 27, 1993Assignee: Takeda Chemical Industries, Ltd.Inventors: Tomoh Masaki, Masashi Yanagisawa, Akihiro Inoue
-
Patent number: 5231176Abstract: This invention related to the discovery and production by recombinant DNA technology of a novel, distinct family of human leukocyte interferons, having a total amino acid residue number greater than 166 preferably about 172.Type: GrantFiled: June 9, 1992Date of Patent: July 27, 1993Assignee: Genentech, Inc.Inventors: David V. Goeddel, Harold M. Shepard
-
Patent number: 5225535Abstract: A lymphokine is taught which can be used to activate and stimulate CD3.sup.+, CD4.sup.+ T cells, as well as Sezary leukemic T cells. The lymphokine can be obtained from mitogen-stimulated peripheral blood mononuclear cells or urine of Sezary Syndrome patients. The lymphokine upregulates interleukin-2 receptors.Type: GrantFiled: December 10, 1990Date of Patent: July 6, 1993Assignee: The Wistar InstituteInventors: Elaine C. DeFreitas, J. Todd Abrams
-
Patent number: 5223611Abstract: Human gp130 protein having at least the following properties: (1) the protein has an affinity with a complex of IL-6 (interleukin-6) and an IL-6 receptor (interleukin-6 receptor); (2) the protein shows an apparent molecular weight of 130 kDa in SDS-polyacrylamide electrophoresis; and (3) the protein participates in the transmission of IL-6 signal; DNA coding for the protein, an expression plamid containing the DNA; and a process for production of the protein using the expression plasmid.Type: GrantFiled: May 27, 1992Date of Patent: June 29, 1993Inventor: Tadamitsu Kishimoto
-
Patent number: 5219989Abstract: A protein comprising at least a first functional site having the ability to bind the cap structure of mRNA and a second functional site having the ability to bind a solid support matrix in such a manner as to allow the first functional site to be immobilized and still remain functionally accessible to interact with the cap structure of mRNA. Also within the scope of the present invention is a method for generating a cDNA library mostly containing full-length cDNAs. The method comprises the incubation of a mixture comprising mRNA:cDNA hybrids with 1) a single strand RNA specific nuclease and 2) the above-mentioned protein. The resulting mixture is then passed through a column comprising a support matrix having the ability to bind the second functional site of the above-mentioned protein in order to selectively bind complete mRNA:cDNA hybrids. The mRNA:cDNA hybrids are then competitively eluted with a cap analog and full-length cDNA strands are separated and recovered.Type: GrantFiled: February 24, 1992Date of Patent: June 15, 1993Assignee: McGill UniversityInventors: Nahum Sonenberg, Isaac Edery, Michael Altmann
-
Patent number: 5219994Abstract: A sulfated glycoprotein with a molecular weight of approximately 45 kda inhibits the activation of tissue factor and thus inhibits the coagulation of blood. This glycoprotein can be used for treatment or prevention of intravascular clotting.Type: GrantFiled: February 5, 1992Date of Patent: June 15, 1993Assignee: W. Alton Jones Cell Science Center, Inc.Inventors: Vincenzo Buonassisi, Patricia C. Colburn
-
Patent number: 5218093Abstract: Biologically active variants of epidermal growth factor are provided, comprising tandemly linked units of monomeric EGF. The variants are useful per se as therapeutic agents to promote wound healing. Production of the multimeric EGF by genetically engineered microbial hosts is also described.Type: GrantFiled: March 1, 1989Date of Patent: June 8, 1993Assignee: Allelix Biopharmaceuticals, Inc.Inventors: Zimin Guo, A. Michael Sills, Nigel A. Skipper
-
Patent number: 5215744Abstract: Disclosed is a method of treating tumors capable of being treated with interferon by administering interferon and dipyridamole, or pharmaceutically acceptable salts thereof, in amounts sufficient to enhance the anti-tumor effect of interferon. Further disclosed is a pharmaceutical composition comprising interferon and dipyridamole.Type: GrantFiled: July 2, 1990Date of Patent: June 1, 1993Assignee: Boehringer Ingelheim GmbHInventors: Nobuo Suzuki, Yoshiaki Takakubo
-
Patent number: 5210073Abstract: A composition and method for the treatment of inflammation, rheumatism, autoimmune disease, ischemic damage of organs, drug toxicity and arteriosclerosis comprising human ADF is disclosed.Type: GrantFiled: September 28, 1990Date of Patent: May 11, 1993Assignees: Ajinomoto Co., Inc., Junji YodoiInventors: Junji Yodoi, Atsushi Uchida, Yutaka Tagaya, Akira Mitsui, Tadashi Hirakawa
-
Patent number: 5210183Abstract: This invention relates to a new prote in subfragments thereof with affinity for immunoglobulin A, a process for cloning and expression of the protein, the corresponding vectors and hosts, a process for preparing the organism, a method for preparing the protein, a reagent kit and a pharmaceutical composition comprising the protein or fragments thereof.Type: GrantFiled: November 14, 1988Date of Patent: May 11, 1993Assignee: HighTech Receptor ABInventors: Gunnar Lindahl, Elisabet Frithz, Lars-Olof Heden
-
Patent number: 5202428Abstract: Proteins isolated from novel clonal cell lines grown in culture are mitogenic for fibroblasts, and glial cells; some promote nerve cell survival and are prospectively useful in treating diseases such as Parkinson's and Alzheimer's which result in cell death in the nervous system, as well as in treating patients prone to epileptic seizures and patients suffering from trauma to the CNS. Certain of these proteins may be useful in nerve regeneration as well as in treating such diseases and injuries. Some are particularly useful in promoting lung development. The proteins can be topically applied in suitable compositions for wound-healing applications, and they can be administered parenterally to promote lung development and to treat patients afflicted with nerve damage and/or nerve disease.Type: GrantFiled: September 27, 1990Date of Patent: April 13, 1993Assignee: The Salk Institute for Biological StudiesInventor: David Schubert
-
Patent number: 5202232Abstract: Describes IgA binding protein isolatable from Group B streptococci, methods of isolation and use in immunological testing procedures.Type: GrantFiled: September 16, 1991Date of Patent: April 13, 1993Assignee: The Rockefeller UniversityInventors: Milan Blake, Emil Gotschlich, Gregory J. Russell-Jones
-
Patent number: 5200508Abstract: We disclose the discovery and purification of a tumor antigen that binds the mouse monoclonal antibody L6. Immunohistochemical analysis showed that the antigen is expressed on the membrane surface of LX-1 human lung tumor cells, which retain L6 binding activity when intracerebrally xenografted in nude rats. The antigen is also expressed in the cytoplasm of hypothalamic neurons. Inability of oxytocin and vasopressin hormones to block L6 binding showed that the antigenic epitope resides in neurophysin, the carrier protein associated with the two hormones. Porcine neurophysin did block L6 binding to the antigen. Western blot analysis confirmed that L6-immunoreactivity is neurophysin-related. Immunoaffinity chromatography and gel electrophoresis revealed the antigen molecular weight to be 45000 daltons. Amino-terminal sequencing revealed a 21-amino acid homology with the N-terminus of human pro-pressophysin.Type: GrantFiled: December 12, 1991Date of Patent: April 6, 1993Assignee: The State of Oregon acting by and through the State Board of Higher Education on behalf of Oregon Health Sciences UniversityInventors: Gajanan Nilaver, Lawrence Rosenbaum, Edward A. Neuwelt
-
Patent number: 5200395Abstract: The polypeptides BUF-4 and BUF-5 may be used to treat osteoporosis, cancer, and anemia, and pharmaceutical compositions containing BUF-4 and/or BUF-5 are disclosed.Type: GrantFiled: October 29, 1991Date of Patent: April 6, 1993Assignee: Ajinomoto Company, Inc.Inventors: Yuzuru Eto, Naoto Koyama, Daisuke Ejima, Masayo Washitake, Hiroshiro Shibai
-
Patent number: 5200176Abstract: Methods suitable for the protection, inhibition and prevention the deleterious effects of reactive oxygen species are provided, wherein an effective amount of a tumor necrosis factor is administered. Pretreatment of tissues and organs to be transplanted is described. Perfusion solutions and the preparation of perfused, excised tissue are described.Type: GrantFiled: October 6, 1989Date of Patent: April 6, 1993Assignee: Genentech, Inc.Inventors: Grace H. W. Wong, David V. Goeddel
-
Patent number: 5198542Abstract: Disclosed are (1) a DNA containing a DNA segment coding for PACAP38; (2) a precursor protein of PACAP38; (3) a transformant containing a DNA having a DNA segment coding for PACAP38; (4) a method of preparing mature PACAP38 comprising cultivating the transformant described in the above (3), producing and accumulating a protein in a culture, and collecting the resulting protein; and (5) a method for preparing the above polypeptide comprising condensing a partial amino acid or a peptide which can constitute the mature PACAP38, with a residual portion, and removing a protective group if a product has the protective group. The DNA is applied to experimental animals to understand their brain functions, which serves to elucidate human brain functions. PACAP38 provides information about growth and maintenance of rat and human brain nerves, and can also be utilized as therapeutic agents for various neuropathy.Type: GrantFiled: June 10, 1990Date of Patent: March 30, 1993Assignee: Takeda Chemical Industries, Inc.Inventors: Haruo Onda, Akira Arimura, Chiharu Kimura, Chieko Kitada
-
Patent number: 5196513Type: GrantFiled: July 25, 1991Date of Patent: March 23, 1993Assignee: Mayo Foundation for Medical Education and ResearchInventors: Robert J. Ryan, Daniel J. McCormick, John C. Morris
-
Patent number: 5190751Abstract: Human leukemia T-cells and B-cells are inhibited from proliferating by treatment with a combination of recombinant human alpha and gamma interferons, either simultaneously or sequentially, and the alpha interferon is preferably recombinant human alfa-2b interferon.Type: GrantFiled: September 26, 1991Date of Patent: March 2, 1993Assignee: Schering CorporationInventor: Paul P. Trotta